Pelthos Therapeutics

Pelthos is a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs.

[Pelthos Therapeutics @PelthosT]

On August 13, the Pelthos management team will review our Q2 2026 financial results. Register for the webcast here: https://t.co/mSOIR4TJOK

[Pelthos Therapeutics @PelthosT]

Our team will be onsite at the Society for Pediatric Dermatology Meeting in Minneapolis this week. We look forward to engaging with the pediatric dermatology community and sharing insights to advance patient care. https://t.co/nnXadfzOY9 #SPD2026

#SPD2026

[Pelthos Therapeutics @PelthosT]

Join us at #DERM2026 this week. Stop by Booth #114 to meet the Pelthos team and learn more about our growing cutaneous infectious disease portfolio. https://t.co/jXC7sPXkWx

[Pelthos Therapeutics @PelthosT]

Today marks one year since Pelthos began trading on the @NYSE American. Since then, we've launched ZELSUVMI®, expanded our portfolio, and secured up to $50M in financing. Thank you to our employees, shareholders, and partners for being part of this journey.

[Pelthos Therapeutics @PelthosT]

Pelthos has been added to the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap® Growth Benchmark Indexes effective June 29 as part of @FTSERussell #RussellRecon. https://t.co/0DZMjEYdpS

[Pelthos Therapeutics @PelthosT]

Pelthos is proud to support @MauiDerm NP+PA Summer 2026, bringing together dermatology NPs, PAs, and industry leaders committed to advancing patient care. We look forward to connecting with attendees in Colorado Springs. Learn more: https://t.co/7GFm9Iopjx

[Pelthos Therapeutics @PelthosT]

Pelthos will present at the @Jefferies Global Healthcare Conference in New York on June 4. CEO Scott Plesha will provide an update on the company’s strategy, commercial progress, and long-term growth outlook. Read more: https://t.co/hOfkCaz1ua

[Pelthos Therapeutics @PelthosT]

Today, we honor and remember the service members who sacrificed their lives for our country. Their dedication will always be remembered, and today we reflect with gratitude on the freedoms they fought to protect. #MemorialDay

[Pelthos Therapeutics @PelthosT]

Today we reported Q126 results, highlighting the continued momentum for our lead product ZELSUVMI—with net product revenue increasing 17% and dispensed prescription units increasing 25% QoQ. Read the release: https://t.co/Th9gQeuiEm

[Pelthos Therapeutics @PelthosT]

Pelthos will report Q1 2026 financial results before the opening of the U.S. financial markets on March 14 followed by a conference call at 8:30am ET. Register: https://t.co/ZFmBVe0FJo

[Pelthos Therapeutics @PelthosT]

Pelthos to participate in the Piper_Sandler Spring Biopharma Symposium this week in Boston. CEO Scott Plesha will host 1x1 investor meetings to discuss our corporate strategy and outlook. https://t.co/iumXUpIsSV

[Pelthos Therapeutics @PelthosT]

Today, we announced that the first patient has been dosed in the Phase 1b/2a trial of CT2000, a novel NaV1.7 inhibitor. This is a meaningful step in advancing Channel’s pipeline of eye pain treatments. https://t.co/nsplotc8ex

[Pelthos Therapeutics @PelthosT]

Pelthos will be at #AAD2026. Stop by Booth #2661 to connect with our team and learn more about our growing commercial product platform.

[Pelthos Therapeutics @PelthosT]

Today we reported Q4 & FY25 results, highlighting a transformational year for Pelthos—advancing the launch of ZELSUVMI, expanding into a multi-product platform, and strengthening our balance sheet. We believe we are well-positioned for continued growth. https://t.co/CazO90tFcd

[Pelthos Therapeutics @PelthosT]

Our CEO, Scott Plesha, will discuss Pelthos' corporate strategy and outlook during a fireside chat at the 38th Annual ROTH Conference on March 23. View the announcement here: https://t.co/SRKzP3epMk

[Pelthos Therapeutics @PelthosT]

Pelthos will report Q4 2025 financial results before the opening of the U.S. financial markets on March 19 followed by a conference call at 8:00am ET. Register: https://t.co/PHFkAu0qMD

[Pelthos Therapeutics @PelthosT]

@Piper_Sandler initiates coverage of Pelthos, expanding our analyst research coverage to 6 firms. This coverage reflects growing recognition of our market opportunity and operational momentum.

[Pelthos Therapeutics @PelthosT]

Pelthos CEO Scott Plesha will discuss our corporate strategy, recent transactions, and financial outlook during the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26. Read the announcement here: https://t.co/MAiYGaLt2B

[Pelthos Therapeutics @PelthosT]

We are pleased to announce that our team will be at the Masters of Pediatric Dermatology Symposium this week in Miami. Join us this Friday as Mercedez Gonzalez, MD, FAAD, discusses our lead FDA-approved product for molluscum contagiosum. https://t.co/puThZ2JDZs

[Pelthos Therapeutics @PelthosT]

This weekend our team is heading to the @MauiDerm Hawaii 2026 conference. Join us on Tuesday, January 27 as Neal D. Bhatia, MD, FAAD discusses our lead FDA-approved product for molluscum contagiosum. Learn more: https://t.co/YlfCwCvcFs #MauiDerm2026